Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Atorvastatin Stories

2011-08-15 06:35:00

KUALA LUMPUR, Malaysia, Aug. 15, 2011 /PRNewswire/ -- The leading website about lowering cholesterol naturally, All-About-Lowering-Cholesterol.com (http://www.all-about-lowering-cholesterol.com), unequivocally recommends that all patients with high cholesterol educate themselves on natural methods for lowering cholesterol, before they ever think of using any statin drug. This education becomes even more important now, since there are voices recommending that some statin drugs may be...

6fc0a6e0493b5d09890cfcaf2104d165
2011-08-04 10:34:48

US regulators will be considering a plan from pharmaceutical giant Pfizer to introduce an over-the-counter version of its top-selling heart drug Lipitor. Selling the popular anti-cholesterol drug without a prescription could help Pfizer's bottom line as the company faces a "patent cliff" that threatens to erode profits during the next few years, according to the Wall Street Journal. Lipitor will soon lose patent protection and face competition from cheaper generic versions of its popular...

2011-07-18 16:15:32

A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to a new analysis in Circulation: Journal of the American Heart Association. Researchers made the finding while analyzing data from a clinical trial on the drug torcetrapib that was halted five years ago. Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor, a type of drug that increases levels of...

2011-07-15 09:30:00

EDISON, N.J., July 15, 2011 /PRNewswire/ -- Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase. This group of drugs has had a controversial history, starting with Baycol, a drug similar to Crestor and Zocor, touted as a "super statin" before its recall from the market. Despite numerous objections from medical researchers and...

2011-06-08 14:32:00

Increased risk of muscle injury cited SILVER SPRING, Md., June 8, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The agency is recommending...

2011-06-07 10:55:00

FRANKLIN LAKES, N.J., June 7, 2011 /PRNewswire/ -- Patients with high cholesterol who regularly take their cholesterol-lowering medications have significantly fewer hospitalizations from cardiovascular problems and can reduce their health care costs by as much as $944 over 18 months, according to research published in the June 1 issue of the American Journal of Cardiology. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) The study conducted by the Medco Research...

2011-05-23 23:25:10

Penn led study identifies ways to reduce wasteful and sometimes even harmful practices A physician panel in the primary care specialty of internal medicine has identified common clinical activities where changes in practice could lead to higher quality care and better use of finite clinical resources. The study identifying the Top 5 list of internal medicine activities appears online in the Archives of Internal Medicine. "Our aim was to come up with a list of best practices via consensus from...

2011-04-18 07:00:00

HAYWARD, Calif., April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes (ACS) will continue based on the positive outcome of an interim biomarker analysis and review of available patient safety data. An independent statistician completed an analysis of various...

2011-04-18 01:00:00

MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses. The purpose of the ANCHOR trial was to demonstrate that...

7d332a7f69a090139fee4ee58f64653b1
2011-03-29 06:11:54

More evidence has linked the cholesterol-lowering drug Lipitor to an increased risk of type 2 diabetes, especially in patients who have multiple diabetes risk factors, according to a study published on Monday. A number of previous studies have linked Lipitor and other cholesterol medications (statins) to a small increase in the risk of diabetes. And the new study, based on data from three large clinical trials, further supports that connection. But the new study also suggests the risk might...